DBV Technologies Announces Leadership Changes
24 Novembre 2020 - 7:30AM
DBV Technologies Announces Leadership Changes
Montrouge, France, November 24, 2020
DBV Technologies Announces Leadership
Changes
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that Dr. Hugh Sampson
has decided to step down from his role as Chief Scientific Officer
(CSO) at DBV, effective December 1, 2020, to return to his research
program at the Jaffe Food Allergy Institute at Mount Sinai. While
acting as CSO, Dr. Sampson continued his commitment to the food
allergy community by directing his research lab, running a
NIH-sponsored prevention trial, and seeing patients in clinical
practice part-time.
Dr. Sampson will take on a new role as
Scientific Adviser to the Chief Executive Officer and Chairman of
DBV’s Scientific Advisory Board. In this capacity, he will remain
involved in DBV’s ongoing development of epicutaneous immunotherapy
(EPIT™).
After three years serving on DBV’s Scientific
Advisory Board, Dr. Sampson joined DBV in 2015 to formally lead the
Company’s global scientific efforts and explore potential new
applications of investigational Viaskin™ for the treatment of food
allergies and autoimmune disorders, and for the development of
novel vaccines. Dr. Sampson is the Kurt Hirschhorn Professor of
Pediatrics at the Icahn School of Medicine at Mount Sinai and the
Director Emeritus of the Jaffee Food Allergy Institute. He is a
member of the National Academy of Medicine, past chair of the
Section on Allergy & Immunology of the American Academy of
Pediatrics and the past-president of the American Academy of
Allergy, Asthma and Immunology.
“Hugh is universally regarded as a leader in
medical research in food allergy and immunology. We’re honored that
he has contributed his remarkable expertise to advancing the
Viaskin™ platform and shaping the scientific approach to our
potential food allergy treatments. Today’s announcement is part of
a thoughtful transition process, and we are grateful that he will
continue to be an integral part of our team in his new role,” said
Daniel Tassé, DBV’s Chief Executive Officer. “I’d like to thank
Hugh for his commitment to our pursuit of improving patient
outcomes and his ongoing, steadfast leadership.”
“I have always been impressed by the dedication
and energy of everyone at DBV, and it has been an honor for me to
act as DBV’s Chief Scientific Officer for the past five years,”
said Dr. Sampson. “I am proud of what DBV has accomplished in
better understanding the biology of EPIT and its potential
applications. Now is the right time for me to return to Mount Sinai
and focus on my research programs in novel diagnostics and
prevention of food allergy. We have worked with purpose to advance
the potential behind the clinical profile of EPIT, and I am excited
by the possibility that it may be a viable treatment option for
millions of patients. I look forward to continuing to work with DBV
to advance their efforts in my new capacity as Scientific Advisor
to Daniel.”
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France and offices in Bagneux, France, and North American
operations in Summit, NJ and New York, NY. The Company’s ordinary
shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), and the Company’s ADSs (each representing
one-half of one ordinary share) are traded on the Nasdaq Global
Select Market (Ticker: DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding the potential benefits of Viaskin
Peanut, the Company’s continued development of epicutaneous
immunotherapy, and the Company’s transition plans. These
forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this
stage, the Company’s products have not been authorized for sale in
any country. Among the factors that could cause actual results to
differ materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals,
including the impact of the COVID-19 pandemic. Furthermore, the
timing of any action by any regulatory agency cannot be guaranteed.
A further list and description of these risks, uncertainties and
other risks can be found in the Company’s regulatory filings with
the French Autorité des Marchés Financiers, the Company’s
Securities and Exchange Commission filings and reports, including
in the Company’s Annual Report on Form 20-F for the year ended
December 31, 2019, and future filings and reports by the Company.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements and estimates, which
speak only as of the date hereof. Other than as required by
applicable law, DBV Technologies undertakes no obligation to update
or revise the information contained in this Press Release.
Investor Relations Contact Anne
Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com
Media ContactAngela Marcucci+1
(646) 842-2393angela.marcucci@dbv-technologies.com
Grafico Azioni DBV Technologies (EU:DBV)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni DBV Technologies (EU:DBV)
Storico
Da Apr 2023 a Apr 2024